Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Cash from Financing Activities came in at -$6.9 million in Q1 2026, down 14370.83% year-on-year from N/an in Q1 2025, and down 40758.82% quarter-over-quarter from -$17000.0 in Q3 2025.
Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Prothena Corp Public's Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$6.9 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 14370.83% year-over-year to -$6.9 million in Q1 2026; TTM through Mar 2026 was -$7.0 million, a 1150.3% decrease from a year earlier, with the FY2025 full-year figure at -$139000.0, down 108.94% from the prior year.
- Cash from Financing Activities eased to -$6.9 million in Q1 2026 per PRTA's latest filing, from -$17000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $220.8 million in Q4 2022 and bottomed at -$6.9 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $659500.0 (2023), against an average of $17.6 million.
- Across the five-year window, Cash from Financing Activities surged 12351.49% in 2022 and slumped 14370.83% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $220.8 million in 2022, then slumped by 99.78% to $483000.0 in 2023, then tumbled by 112.22% to -$59000.0 in 2024, then surged by 71.19% to -$17000.0 in 2025, then plunged by 40758.82% to -$6.9 million in 2026.
- Per Business Quant, the three latest PRTA Cash from Financing Activities figures stand at -$6.9 million (Q1 2026), -$17000.0 (Q3 2025), and -$74000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | -6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.95 Mn |
| Mar 31, 2026 | -6.95 Mn |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -74,000.00 |
| Jun 30, 2025 | -74,000.00 |
| Mar 31, 2025 | -48,000.00 |
| Mar 31, 2025 | -48,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Jun 30, 2024 | 444,000.00 |
| Jun 30, 2024 | 444,000.00 |
| Mar 31, 2024 | 836,000.00 |
| Mar 31, 2024 | 836,000.00 |
| Dec 31, 2023 | 483,000.00 |
| Dec 31, 2023 | 483,000.00 |
| Sep 30, 2023 | 2.71 Mn |
| Sep 30, 2023 | 2.71 Mn |